Related Experiment Videos
Structural insights into the activation of P. vivax plasmepsin
Nina Khazanovich Bernstein1, Maia M Cherney, Charles A Yowell
1CIHR Group in Protein Structure and Function, Department of Biochemistry, University of Alberta, Edmonton, Alberta, Canada T6G 2H7.
Abstract:
The malarial aspartic proteinases (plasmepsins) have been discovered in several species of Plasmodium, including all four of the human malarial pathogens. In P.falciparum, plasmepsins I, II, IV and HAP have been directly implicated in hemoglobin degradation during malaria infection, and are now considered targets for anti-malarial drug design. The plasmepsins are produced from inactive zymogens, proplasmepsins, having unusually long N-terminal prosegments of more than 120 amino acids. Structural and biochemical evidence suggests that the conversion process of proplasmepsins to plasmepsins differs substantially from the gastric and plant aspartic proteinases. Instead of blocking substrate access to a pre-formed active site, the prosegment enforces a conformation in which proplasmepsin cannot form a functional active site. We have determined crystal structures of plasmepsin and proplasmepsin from P.vivax. The three-dimensional structure of P.vivax plasmepsin is typical of the monomeric aspartic proteinases, and the structure of P.vivax proplasmepsin is similar to that of P.falciparum proplasmepsin II. A dramatic refolding of the mature N terminus and a large (18 degrees ) reorientation of the N-domain between P.vivax proplasmepsin and plasmepsin results in a severe distortion of the active site region of the zymogen relative to that of the mature enzyme. The present structures confirm that the mode of inactivation observed originally in P.falciparum proplasmepsin II, i.e. an incompletely formed active site, is a true structural feature and likely represents the general mode of inactivation of the related proplasmepsins.
Insights
Malaria parasites use special enzymes called plasmepsins to break down hemoglobin. Structural studies reveal how inactive plasmepsin zymogens prevent active site formation, offering new anti-malarial drug targets.
Area of Science:
- Biochemistry
- Structural Biology
- Parasitology
Background:
- Plasmepsins are malarial aspartic proteinases crucial for hemoglobin degradation by Plasmodium species.
- Plasmepsins are synthesized as inactive zymogens (proplasmepsins) with long N-terminal prosegments.
- Proplasmepsin activation differs from other aspartic proteinases, suggesting unique inactivation mechanisms.
Purpose of the Study:
- To determine the crystal structures of plasmepsin and proplasmepsin from Plasmodium vivax.
- To elucidate the structural basis for the auto-inhibition of proplasmepsins.
- To provide insights into potential anti-malarial drug targets.
Main Methods:
- X-ray crystallography was used to determine the three-dimensional structures of P. vivax plasmepsin and proplasmepsin.
- Comparative structural analysis of proplasmepsin and plasmepsin structures.
Main Results:
- The crystal structure of P. vivax plasmepsin resembles typical monomeric aspartic proteinases.
- The P. vivax proplasmepsin structure is similar to P. falciparum proplasmepsin II.
- Significant conformational changes, including N-terminal refolding and domain reorientation, distort the active site in proplasmepsin, preventing its function.
Conclusions:
- The auto-inhibition mechanism of proplasmepsins involves an incompletely formed active site, not just substrate access blocking.
- This structural feature is likely conserved across related proplasmepsins.
- Understanding these structures provides a basis for designing novel anti-malarial drugs targeting plasmepsins.